Recent news on Octreotide

Ambrilia Announces First Quarter 2007 Results and Provides Update ...  -  May 9, 2007
CCNMatthews (press release),Ambrilia initiated a pivotal Phase III clinical trial in Europe with its improved prolonged- release formulation of Octreotide in acromegaly patients.

Ambrilia Announces Conference Call and Webcast Details for First ...  -  May 8, 2007
Genetic Engineering News (press release),...two new formulations of existing drugs developed with a patented technology (Octreotide and Goserelin), an anti-cancer therapeutic peptide (PCK3145),

68 Ga-DOTA-Tyr 3 -Octreotide PET in Neuroendocrine Tumors ...  -  Mar 30, 2007
Journal of Nuclear Medicine (subscription)Imaging results of PET were compared with 99m Tc-labeled hydrazinonicotinyl-Tyr 3 -octreotide ( 99m Tc-HYNIC-TOC) and 111 In-DOTA-TOC.

Ambrilia Announces the Appointment of Stephen G. Sudovar as ...  -  Apr 18, 2007
SYS-CON Media,...important progress in our lead product candidates such as Octreotide", said Hans J. Mader, former President and Chief Executive Officer of Ambrilia.

Ambrilia Announces Fiscal 2006 Results  -  Mar 27, 2007
CCNMatthews (press release),Oct. 06: Positive pivotal human pharmacokinetic study results for Ambrilia's improved formulation of Octreotide to treat acromegaly.

Study Shows Ambrilia's Therapeutic Peptide PCK3145 Has Clinical ...  -  Apr 24, 2007
PipelineReview.com (press release),...two new formulations of existing drugs developed with a patented technology (Octreotide and Goserelin), an anti-cancer therapeutic peptide (PCK3145),

Novartis licences lead cancer candidate from Antisoma  -  Apr 23, 2007
In-PharmaTechnologist.com,If approved, AS1404 will add to its current arsenal of anticancer treatments: Femara (letrozole), Glivec (imatinib), Sandostatin LAR (octreotide acetate)

Indevus and Valera complete merger  -  Apr 19, 2007
News-Medical.net,...of particular milestones with respect to three Valera product candidates in development - Supprelin-LA, ureteral stent and VP003 (Octreotide implant).

A Case Report and Review of the Literature  -  Apr 12, 2007
Medscape (subscription)A case of pancreatic pleural effusion and mediastinal pancreatic pseudocyst: Management by a somatostatin analogue octreotide. Pancreas. 1999;19:410-412.

Current Treatment of Malignant Pheochromocytoma  -  Apr 4, 2007
Journal of Clinical Endocrinology and Metabolism,Octreotide as a single agent seems to be largely ineffective. Conclusions: MIBG radiotherapy and cyclophosphamide, vincristine, and dacarbazine chemotherapy

Indication for Different Mechanisms of Kidney Uptake of ...  -  Mar 30, 2007
Journal of Nuclear Medicine (subscription)Methods: Male Wistar rats (4 per group) were injected intravenously with 1 MBq of 111 In-labeled octreotide (OCT), minigastrin (MG), bombesin (BOM),

Ambrilia to Host Fiscal Year 2006 Results Conference Call and Webcast  -  27 Mar 2007
Market Wire (press release)...two new formulations of existing drugs developed with a patented technology (Octreotide and Goserelin), an anti-cancer therapeutic peptide (PCK3145),

Ambrilia and Mallinckrodt Announce IND Filing for Phase III ...  -  Mar 14, 2007
PipelineReview.com (press release),..."Mallinckrodt has the sales and marketing expertise to reach specialists who will prescribe Octreotide throughout the United States along with a track

"I'm Not Ready for Hospice": Strategies for Timely and Effective ...  -  Mar 19, 2007
Annals of Internal MedicineShe was admitted to the hospital 3 days ago for malignant bowel obstruction, which has improved with bowel rest, intravenous fluids, and octreotide.

Callisto Pharmaceuticals Opens Additional Site For Phase II ...  -  Mar 13, 2007
Medical News Today (press release),...neuroendocrine carcinoma who have metastatic or unresectable cancer and who have progression of their disease despite standard therapy (octreotide).

Callisto Pharmaceuticals Opens Additional Site for Phase II ...  -  Mar 12, 2007
Earthtimes.org...gradeneuroendocrine carcinoma who have metastatic or unresectable cancer and whohave progression of their disease despite standard therapy (octreotide).

Octreotide of No Benefit in Advanced Liver Cancer  -  Jan 26, 2007
Cancerpage.com,Previous non-randomized and non-placebo-controlled clinical trials have suggested a positive effect of octreotide in patients with HCC.

Octreotide may help some with Graves' ophthalmopathy  -  Jan 31, 2007
Therapeutics Daily (subscription) (press release),NEW YORK (Reuters Health) - Long-acting release octreotide appears to have beneficial effects in certain patients with Graves' ophthalmopathy, according to

'Death sentence' for rare cancer sufferer refused £15k treatment  -  Feb 14, 2007
ic Wales,But doctors at the Royal Free Hospital in London testing a new kind of treatment known as yttrium octreotide therapy used Mr Davies as a research guinea pig

Callisto Pharmaceuticals Opens Second Site For Phase II Clinical ...  -  Feb 1, 2007
Medical News Today (press release),...neuroendocrine carcinoma who have metastatic or unresectable cancer and who have progression of their disease despite standard therapy (octreotide).

Callisto Pharmaceuticals Opens Second Site for Phase II Clinical ...  -  Jan 31, 2007
Earthtimes.org...gradeneuroendocrine carcinoma who have metastatic or unresectable cancer and whohave progression of their disease despite standard therapy (octreotide).

Ambrilia Announces Election of New Chairman and Appointment of New ...  -  Jan 30, 2007
Genetic Engineering News (press release),...a Tumor Vasculature Targeting (TVT) technology platform, two improved formulations of existing drugs (Octreotide and Goserelin) developed with a

Long-acting octreotide no better than a placebo, study finds  -  Jan 9, 2007
CBC News,One such treatment, a drug called short-acting octreotide, was shown to improve survival, but the twice-daily administration of the drug was associated with

No Benefit For Liver Cancer Patients From Long-Acting Octreotide  -  Jan 8, 2007
Medical News Today (press release),Long-acting octreotide does not improve outcomes for patients with liver cancer compared to a placebo, according to the results of a new double blind study

No Benefit for Liver Cancer Patients From Long-Acting Octreotide  -  Jan 3, 2007
DG NewsHOBOKEN, NJ -- January 3, 2007 -- Long-acting octreotide does not improve outcomes for patients with liver cancer compared to a placebo, according to the

Radiation Dose Distribution in Human Kidneys by Octreotides in ...  -  Jan 4, 2007
Journal of Nuclear Medicine (subscription)Ex vivo autoradiographs of healthy kidney tissue from patients who received 111 In-DTPA-octreotide (DTPA is diethylenetriaminepentaacetic acid) before

Long-Acting Sandostatin Not Therapeutic for Liver Cancer  -  Jan 3, 2007
MedPage Today,3 -- Long-acting release Sandostatin (octreotide) appears to have no benefit for hepatocellular carcinoma either in clinical outcomes or quality of life,

Randomized, Double-Blind, Placebo-Controlled Trial of Long-Acting ...  -  Dec 5, 2006
Journal of Clinical Endocrinology and Metabolism,Objective: The objective of the study was to determine whether octreotide long-acting release (LAR) is effective treatment for active GO.

Ambrilia Announces Further Distribution Partnerships for Europe ...  -  Dec 5, 2006
CCNMatthews (press release),Archimedes Pharma Ltd., a European specialty pharmaceutical company with a growing specialist-focused commercial presence, will distribute Octreotide in the

Indevus Pharmaceuticals to Acquire Valera Pharmaceuticals  -  Dec 13, 2006
PipelineReview.com (press release),Other products in development by Valera include a biodegradable ureteral stent for post-kidney stone lithotripsy and an octreotide implant for the treatment

National Patent Development Announces Proposed Valera ...  -  Dec 14, 2006
Business Wire (press release),...of Valera’s biodegradable ureteral stent and one CSR is convertible into $1.50 of Indevus common stock upon FDA approval of Valera’s octreotide implant.

Indevus To Acquire Valera For $120 Mln In Stock Transaction Plus ...  -  Dec 12, 2006
Trading Markets,...biodegradable ureteral stent, while the third CSR would be convertible into $1.50 of Indevus common stock upon FDA approval of the octreotide implant.

Indevus Buying Valera  -  Dec 12, 2006
TheStreet.com...approval of the biodegradable ureteral stent and one CSR is convertible into $1.50 of Indevus common stock upon FDA approval of the octreotide implant.

Ambrilia Announces that Phase 1 Study Results Support Continued ...  -  Dec 8, 2006
Genetic Engineering News (press release),...prolonged release formulation of Octreotide, a new formulation of Goserelin, promising anti-HIV treatments (PPL-100, HIV Integrase Inhibitor Program),

Ambrilia to Host Third Quarter 2006 Results Conference Call  09 Nov 2006
...includes an anti-cancer therapeutic peptide (PCK3145), a novel anti-cancer therapy (TVT-Dox), two oncology specialty generics (Octreotide, Goserelin), the ... -Market Wire (press release) Study Finds Cost Savings With Prophylactic Octreotide in High-Risk ...  Oct 11, 2006
Octreotide reduces exocrine secretions from the pancreas, but it only works in people at high risk to develop a fistula," Vanounou said. ... -DG News Valera Pharmaceuticals Reports Third Quarter 2006 Financial ...  Nov 8, 2006
Valera's Phase I/II(a) clinical trials of its octreotide implant for treating acromegaly, or giantism, originally employed 50 mg and 100 mg of the active agent ... -Market Wire (press release) Ambrilia Announces Positive Results of a Pivotal Human ...  Oct 26, 2006
...oncology and infectious diseases, announced today positive results of a pivotal pharmacokinetic (PK) study of its lead specialty generic, Octreotide, for the ... -Market Wire (press release) Ambrilia Announces Positive Results of a Pivotal Human ...  Oct 27, 2006
Announced today positive results of a pivotal pharmacokinetic (PK) study of its lead specialty generic, Octreotide, for the treatment of acromegaly. ... -PipelineReview.com (press release), Callisto Pharmaceuticals Initiates Phase II Clinical Trial Of ...  Nov 8, 2006
...grade neuroendocrine carcinoma who have metastatic or unresectable cancer and who have either symptoms, despite standard therapy (octreotide), or progression ... -Medical News Today (press release), Pasireotide Suppresses Growth Hormone in Active Acromegalics ...  Sep 18, 2006
The study administered 4 weeks of octreotide (100 mcg sc 3 times daily) followed by a randomized, 3-period crossover phase of low, medium and high doses of ... -DG News

Ambrilia to Present at UBS Global Life Sciences Conference in New ...  Sep 19, 2006
...includes an anti-cancer therapeutic peptide (PCK3145), a novel anticancer therapy (TVT-Dox), two oncology specialty generics (Octreotide, Goserelin), the first ... -PharmaLive.com

Dosimetry in Peptide Radionuclide Receptor Therapy: A Review *  Sep 5, 2006
FIGURE 1. Dosimetric data published for principal PRRT trials: (A) 111 In-DTPA-octreotide (Stabin (13), Forster (22), Helish (23), Kwekkeboom (14)). ... -Journal of Nuclear Medicine (subscription)

Nuclear Medicine Division, Radiology Department, Aretaieion ...  Sep 5, 2006
The aim of the study was to provide dosimetric data on intrahepatic 111 In-diethylenetriaminepentaacetic acid (DTPA)-D-Phe 1 -octreotide therapy for ... -Journal of Nuclear Medicine (subscription)

Indevus Pharmaceuticals to Acquire Valera Pharmaceuticals  -  12 Dec 2006
Drug Newswire (press release),Other products in development by Valera include a biodegradable ureteral stent for post-kidney stone lithotripsy and an octreotide implant for the treatment

Ambrilia Announces Further Distribution Partnerships for Europe ...  -  Dec 5, 2006
CCNMatthews (press release),Archimedes Pharma Ltd., a European specialty pharmaceutical company with a growing specialist-focused commercial presence, will distribute Octreotide in the

Ambrilia Announces European Licensing Partnership with TEVA for ...  -  Nov 16, 2006
PipelineReview.com (press release),TEVA Europe, a subsidiary of the global generic pharmaceutical leader Teva Pharmaceutical Industries Ltd., is Octreotide's licensee for France, Germany,

Ambrilia Announces Third Quarter 2006 Results and Provides Update ...  -  Nov 14, 2006
CCNMatthews (press release),For Ambrilia, other potential opportunities such as Octreotide and PCK3145 are within reach in a near future. I believe that investing in these and other

Ambrilia Announces Third Quarter 2006 Results and Provides Update ...  -  Nov 14, 2006
Genetic Engineering News (press release),Reported positive results of a pivotal human pharmacokinetic study of Ambrilia's new prolonged release formulation of Octreotide. - Welcomed a new member to

Ambrilia Announces that Phase 1 Study Results Support Continued ...  -  Dec 8, 2006
Genetic Engineering News (press release),...prolonged release formulation of Octreotide, a new formulation of Goserelin, promising anti-HIV treatments (PPL-100, HIV Integrase Inhibitor Program),

Kidney Progress: Drug slows cyst growth  -  Nov 24, 2006
Science NewsMeanwhile, several other drugs, including rapamycin, octreotide, and tolvaptan, that succeeded in animal tests for PKD are now being tested in people.

Increased Uptake of 111 In-Octreotide in Idiopathic Pulmonary ...  Aug 1, 2006
A modulation of fibroblast activation has been observed in various systems with octreotide, a synthetic somatostatin analog with strong affinity for the ... -Journal of Nuclear Medicine (subscription)

Ambrilia Announces Second Quarter 2006 Results and Provides Update ...  Aug 10, 2006
...and pharmacokinetics after repeated oral dosing with PPL-100. Octreotide in comparison to Sandostatin ® LAR in human subjects. ... -CCNMatthews

Ambrilia Announces Second Quarter 2006 Results and Provides Update ...  Aug 10, 2006
...from our US partner due upon the successful manufacturing of sterile batches of lead late-stage oncology specialty generic, Octreotide, meeting stability ... -Market Wire

Ambrilia Announces Receipt of Milestone Payment from US Licensing ...  Aug 2, 2006
...payment resulting from an agreement with its licensing partner in the United States for its late-stage oncology specialty generic, Octreotide, for the ... -PipelineReview.com

Ambrilia Appoints Mr. Luc Tanguay to its Board of Directors  Aug 22, 2006
...includes an anti-cancer therapeutic peptide (PCK3145), a novel anti-cancer therapy (TVT-Dox), two oncology specialty generics (Octreotide, Goserelin), the ... -Market Wire

Pegvisomant for the Treatment of gsp-Mediated Growth Hormone ...  Aug 7, 2006
...other medications (long-acting octreotide ± dopamine agonist) in the same group showed that the two regimens were similarly effective. ... -Journal of Clinical Endocrinology and Metabolism

Abraxis BioScience Reports Second Quarter 2006 Adjusted Earnings ...  Aug 3, 2006
In the second quarter, the Abraxis Pharmaceutical Products division launched three new products, carboplatin 600 mg, mitoxantrone and octreotide. ... -PharmaLive.com

Ipsen and Tercica to Enter into Worldwide Strategic Collaboration ...  Jul 18, 2006
Source: IMS MIDAS/Ex-manufactures as a percentage of sales of sustained release formulations of the specific molecules lanreotides, octreotide and pegvisomant ... -Canada NewsWire

Low Risk for Development of Cardiac Valve Regurgitation in ...  Jun 30, 2006
...valvular regurgitation was low in patients with acromegaly who were randomized to either of the somastatin analogue treatments lanreotide or octreotide in a ... -DG News

Long-term outcome of bronchoscopically resected endobronchial ...  Jul 15, 2006
If there were concerns on either the history, examination, or chest radiograph, then a CT scan was performed with octreotide labeling if deemed necessary. ... -The Journal of Thoracic and Cardiovascular Surgery



Researchers' findings from the United States and Germany advance ...  May 11, 2006
Study 1: Octreotide LAR given at 40 or 60 mg resulted in statistically significant weight loss in obese adults with insulin hypersecretion. ... - Therapeutics Daily (subscription)

Ambrilia Announces First Quarter 2006 Results and Provides Update ...  May 10, 2006
Effectively implemented a sterile manufacturing chain and produced batches of Octreotide in compliance with clinical use regulations and which showed a ... - Market Wire

Rodman & Renshaw 3rd Annual Global Healthcare Conference 2006 ...  May 11, 2006
Ambrilia's product portfolio includes mid to early-stage products (PPL-100, PCK3145, TVT-Dox, SPC3) and two specialty generics (Octreotide and Goserelin), the ... - Genetic Engineering News

Expression of Protein Kinase CK2 in Astroglial Cells of Normal and ...  May 2, 2006
Here we describe retinal CK2 expression and combined effects of CK2 inhibitors with the somatostatin analog octreotide in a mouse model of oxygen-induced ... - Am J Pathology (subscription)

Pasireotide (SOM230) Shows Promise for Treating Acromegaly ...  May 2, 2006
..."Early data from phase 2 studies in metastatic carcinoid tumors resistant/refractory to Sandostatin LAR [octreotide injection], acromegaly, and Cushing's ... - DG News

Valera Pharmaceuticals Reports First Quarter 2006 Financial ...  Apr 27, 2006
VP003, a six month implant delivering octreotide for the treatment of acromegaly, will enter Phase III clinical trials, rather than Phase IIb trials, later ... - Business Wire

Ambrilia Announces Board Appointments: Joseph J. Krivulka and ...  May 9, 2006
...promising anti-HIV treatments (PPL-100, SPC3), a tumor vasculature targeting technology (TVT-Dox) and two specialty generics (Octreotide, Goserelin), the first ... - Market Wire





Gluc-Lys([ 18 F]FP)-TOCA PET in Patients with SSTR-Positive Tumors ...  Apr 3, 2006
...in patients with sstr-positive tumors by assessing the pharmacokinetics, biodistribution, and diagnostic performance in comparison with [ 111 In]DTPA-octreotide ... - Journal of Nuclear Medicine

Ambrilia Announces Term Extension of Investissement Quebec's ...  Apr 7, 2006
Ambrilia's first generic product is a long acting formulation of the drug Octreotide, used for the treatment of a rare disease called acromegaly caused by a ... - CCNMatthews

Potential Increased Tumor-Dose Delivery with Combined 131 I-MIBG ...  Apr 3, 2006
131 I-Metaiodobenzylguanidine (MIBG) and 90 Y-DOTA-D-Phe1-Tyr3-octreotide (DOTATOC) have been used as radiotherapeutic agents for treating neuroendocrine tumors ... - Journal of Nuclear Medicine

Ambrilia Announces Fiscal 2005 Results and Appointment of Three ...  Mar 22, 2006
...the $18.1 million equity financing that closed on March 1, 2006 and milestones to be received from existing contracts with licensees for Octreotide, to support ... - Genetic Engineering News

Temodar® and Thalomid® Effective for Metastatic Neuroendocrine ...  Mar 21, 2006
The introduction of the long-acting somatostatin analogue Sandostatin® (octreotide) has resulted in significant advances in palliation and in controlling ... - Cancer Consultants



American Pharmaceutical Partners Receives Two FDA Approvals for ...  Feb 13, 2006
...it has received two approvals from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Applications (ANDAs) for Octreotide Acetate Injection ... - PR Newswire,

Internalization of sst 2 , sst 3 , and sst 5 Receptors: Effects of ...  Mar 1, 2006
Y-DOTA-TATE, Y-DOTA-NOC, Lu-DOTA-BOC-ATE (where DOTA is 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid; TATE is [Tyr 3 , Thr 8 ]-octreotide; NOC is [1 ... - Journal of Nuclear Medicine

Procyon Shareholders Approve Cellpep Acquisition  Feb 27, 2006
...stage generics. The first of these products, Octreotide, is expected to be launched in Europe in 2007 and in the US in 2008. The ... - International News Service,

APP Gets FDA OKs for Generic Sandostatin  Feb 14, 2006
American Pharmaceutical Partners has received two approvals from the FDA to market octreotide acetate injection, a generic equivalent of Novartis' Sandostatin ... - International News Service,

Diarrhea: Cancer-related causes and how to cope  Mar 2, 2006
Examples of anti-secretory agents include aspirin, bismuth subsalicylate (Pepto-Bismol), corticosteroids and octreotide. Fiber. ... - MayoClinic.com

Procyon Presents Preclinical Results with its Novel Tumor ...  Feb 7, 2006
The first of these products, octreotide, for which distribution agreements with major pharmaceutical companies have been already concluded, is expected to be ... - Genetic Engineering News,

Manhattan Pharmaceuticals Names Alan Harris Chief Medical Officer  Feb 1, 2006
...(Novartis) in Basel, Switzerland where he developed octreotide (Sandostatin(r)), the first clinically useful, long-acting somatostatin analog approved ... - PharmaLive.com,

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional